Clark Paramore, Head of Global Value Evidence Strategy at Biogen, reflects on a standout event — from timely conversations on MFN and JCA to high-caliber speakers and the invaluable networking opportunities that brought together industry professionals and manufacturers. Watch to hear why events like this matter.
At ACCESS Forum New Orleans 2025, Sarah Emond, President and CEO, Institute for Clinical and Economic Review (ICER), shares why the ACCESS Forum is such a valuable experience: the opportunity to engage with great experts, hear the latest news, and foster meaningful dialogue between companies. She reflects on the rich conversations with fellow manufacturers and the chance to walk away with a wealth of new information — making it a meeting she truly enjoys. Watch to hear why events like this matter.
In the past few years, we’ve witnessed unprecedented policy and pricing reforms. Today they are creating seismic shifts for global market access. Decisions once treated as local or tactical now carry current and future global cross-portfolio consequences.
Net Price Governance Net price decisions made today determine 2026–2028 portfolio value. Organizations that govern net price proactively will protect launch integrity, preserve margin, and stabilize enterprise value.
Proliferation of non-traditional competitors and stakeholders, including non-traditional flow of innovation, and a general perception of inflated cost of healthcare, challenge the legacy model of drug development and commercialization.
Hopes that the UK-US trade agreement would give some clarity on the situation for pharmaceuticals – one of the UK's biggest export categories – proved optimistic.